CYTOGRAFT TISSUE ENGINEERING, INC.

Basic Information

3 HAMILTON LANDING, STE 220
NOVATO, CA, 94949-

Company Profile

n/a

Additional Details

Field Value
DUNS: n/a
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Tau Protein Aggregation Inhibitors for Tauopathies

    Amount: $207,689.00

    DESCRIPTION (provided by applicant): Transcatheter aortic valve implantation (TAVI) is a minimally invasive approach to valve replacement that has had a rapid and profound clinical impact. Less than t ...

    SBIR Phase I 2013 Department of Health and Human Services
  2. Cell-synthesized Thread-based Tissue Engineering

    Amount: $1,473,645.00

    DESCRIPTION (provided by applicant): Cardiovascular disease is the leading cause of death in industrialized nations. While interventional techniques such as angioplasty and/or stenting can often dela ...

    SBIR Phase II 2011 Department of Health and Human Services
  3. Cell-synthesized Thread-based Tissue Engineering

    Amount: $215,415.00

    DESCRIPTION (provided by applicant): Previously, we have reported excellent clinical results with a tissue engineered vascular graft built using a self-assembly approach termed Sheet-Based Tissue Eng ...

    SBIR Phase I 2010 Department of Health and Human Services
  4. Development of a Biological Stent Graft for Aorta Aneurysm Repair

    Amount: $214,912.00

    DESCRIPTION (provided by applicant): Abdominal aorta aneurysms (AAA) are diagnosed in more than 100,000 patients in the U.S. each year. About 70% of these patients require surgical intervention to pre ...

    SBIR Phase I 2010 Department of Health and Human Services
  5. Commercialization of a Tissue Engineered Blood Vessel

    Amount: $2,482,150.00

    DESCRIPTION (provided by applicant): The stated objective for this PA is to fund pre-clinical and clinical tests to support regulatory requirements for promising medical technologies. Accordingly, th ...

    SBIR Phase II 2005 Department of Health and Human Services
  6. in vivo Evaluation of a Tissue Blood Vessel

    Amount: $0.00

    DESCRIPTION (provided by applicant): Coronary heart disease is the leading cause of death in the industrialized world. Despite advances in catheter-based interventions, bypass remains the treatment ...

    SBIR Phase I 2003 Department of Health and Human Services
  7. N/A

    Amount: $98,880.00

    N/A

    SBIR Phase I 2000 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government